Antibodies against human papillomavirus proteins in Barrett's dysplasia and intramucosal esophageal adenocarcinoma.
Barrett's esophagus
esophageal cancer
gastroesophageal reflux disease
human papillomavirus
immune response
serology
Journal
Annals of the New York Academy of Sciences
ISSN: 1749-6632
Titre abrégé: Ann N Y Acad Sci
Pays: United States
ID NLM: 7506858
Informations de publication
Date de publication:
06 2020
06 2020
Historique:
received:
24
12
2019
revised:
10
02
2020
accepted:
17
02
2020
pubmed:
15
3
2020
medline:
6
10
2020
entrez:
15
3
2020
Statut:
ppublish
Résumé
High-risk human papillomavirus (HPV) types 16/18 have been associated with Barrett's dysplasia (BD)/esophageal adenocarcinoma (EAC). Nevertheless, no data exist in relation to serological analysis for HPV antibodies in BD/EAC with site-specific viral DNA status. We prospectively examined antibodies to multiple HPV types in 438 patients representing hospital/reflux controls and Barrett's metaplasia (BM)/BD/intramucosal EAC. Antibody responses to HPV6/11/16/18/31/33/45/52/58 were analyzed using multiplex serology, including antibodies to E6/E7/E1/E2 and L1 antigens. Seropositivity for individual HPV proteins was infrequent in both cases and controls and was ≤10.2%. There was no difference in the seroprevalence of antibodies to any HPV antigen/antibody combination between reclassified cases (BD/EAC) and controls (hospital/reflux/BM) or between HPV16 or HPV18 DNA cases and controls, respectively. Among HPV16 DNA-positive BD/EAC cases, antibodies to HPV16 E7 were significantly more prevalent (3/26, 11.5%) than in hospital and reflux controls plus BM (5/328, 1.5%) (adjusted OR = 10.12, 95% CI: 1.61-63.73, P = 0.014). Among HPV18 DNA-positive cases, antibodies to HPV18 E1 were present in 3/6 (50%) cases versus 5/328 (1.5%) controls (adjusted OR = 44.28, 95% CI: 6.10-321.47, P = 0.0002). Although antibodies against HPV were generally uncommon in cases and controls, immune responses against two early proteins of HPV16/18 were significantly more frequent in viral DNA-positive BD/intramucosal EAC.
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
44-56Informations de copyright
© 2020 New York Academy of Sciences.
Références
Rajendra, S. 2015. Barrett's oesophagus: can meaningful screening and surveillance guidelines be formulated based on new data and rejigging the old paradigm? Best Pract. Res. Clin. Gastroenterol. 29: 65-75.
Pohl, H. & H.G. Welch. 2005. The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J. Natl. Cancer Inst. 97: 142-146.
Lagergren, J. & F. Mattsson. 2011. No further increase in the incidence of esophageal adenocarcinoma in Sweden. Int. J. Cancer 129: 513-516.
Pohl, H., B. Sirovich & H.G. Welch. 2010. Esophageal adenocarcinoma incidence: are we reaching the peak? Cancer Epidemiol. Biomarkers Prev. 19: 1468-1470.
Rajendra, S., B. Wang, E.T. Snow, et al. 2013. Transcriptionally active human papillomavirus is strongly associated with Barrett's dysplasia and esophageal adenocarcinoma. Am. J. Gastroenterol. 108: 1082-1093.
Wang, B., S. Rajendra, D. Pavey, et al. 2013. Viral load and integration status of high-risk human papillomaviruses in the Barrett's metaplasia-dysplasia-adenocarcinoma sequence. Am. J. Gastroenterol. 108: 1814-1816.
Rajendra, S., B. Wang, D. Pavey, et al. 2015. Persistence of human papillomavirus, overexpression of p53, and outcomes of patients after endoscopic ablation of Barrett's esophagus. Clin. Gastroenterol. Hepatol. 13: 1364-1368.e5.
Rajendra, S., B. Wang, N. Merrett, et al. 2016. Genomic analysis of HPV-positive versus HPV-negative oesophageal adenocarcinoma identifies a differential mutational landscape. J. Med. Genet. 53: 227-231.
Rajendra, S., T. Yang, W. Xuan, et al. 2017. Active human papillomavirus involvement in Barrett's dysplasia and oesophageal adenocarcinoma is characterized by wild-type p53 and aberrations of the retinoblastoma protein pathway. Int. J. Cancer 141: 2037-2049.
Rajendra, S., W. Xuan, N. Merrett, et al. 2018. Survival rates for patients with Barrett high-grade dysplasia and esophageal adenocarcinoma with or without human papillomavirus infection. JAMA Netw. Open 1: e181054.
Fakhry, C., W.H. Westra, S.J. Wang, et al. 2017. The prognostic role of sex, race, and human papillomavirus in oropharyngeal and nonoropharyngeal head and neck squamous cell cancer. Cancer 123: 1566-1575.
Ang, K.K., J. Harris, R. Wheeler, et al. 2010. Human papillomavirus and survival of patients with oropharyngeal cancer. N. Engl. J. Med. 363: 24-35.
El-Serag, H.B., J.M. Hollier, P. Gravitt, et al. 2012. Human papillomavirus and the risk of Barrett's esophagus. Dis. Esophagus 5: 517-521.
Rai, N., G.J. Jenkins, E. McAdam, et al. 2008. Human papillomavirus infection in Barrett's oesophagus in the UK: an infrequent event. J. Clin. Virol. 43: 250-252.
Iyer, A., V. Rajendran, C.S. Adamson, et al. 2011. Human papillomavirus is detectable in Barrett's esophagus and esophageal carcinoma but is unlikely to be of any etiologic significance. J. Clin. Virol. 50: 205-208.
Antonsson, A., L. Knight & D.C. Whiteman. 2016. Human papillomavirus not detected in esophageal adenocarcinoma tumor specimens. Cancer Epidemiol. 41: 96-98.
Rajendra, S. & B. Wang. 2016. Human papillomavirus not detected in esophageal adenocarcinoma tumor specimens-letter. Cancer Epidemiol. 43: 119.
Li, X., C. Gao, Y. Yang, et al. 2014. Systematic review with meta-analysis: the association between human papillomavirus infection and oesophageal cancer. Aliment. Pharmacol. Ther. 39: 270-281.
Kunzmann, A.T., S. Graham, C.M. McShane, et al. 2017. The prevalence of viral agents in esophageal adenocarcinoma and Barrett's esophagus: a systematic review. Eur. J. Gastroenterol. Hepatol. 29: 817-825.
Naucler, P., H.-C. Chen, K. Persson, et al. 2007. Seroprevalence of human papillomaviruses and Chlamydia trachomatis and cervical cancer risk: nested case-control study. J. Gen. Virol. 88: 814-822.
Sitas, F., M. Urban, L. Stein, et al. 2007. The relationship between anti-HPV-16 IgG seropositivity and cancer of the cervix, anogenital organs, oral cavity and pharynx, oesophagus and prostate in a black South African population. Infect. Agents Cancer. 2: 6.
Herrero, R., X. Castellsague, M. Pawlita, et al. 2003. Human papillomavirus and oral cancer: the International Agency for Research on Cancer multicenter study. J. Natl. Cancer Inst. 95: 1772-1783.
D'Souza, G., A.R. Kreimer, R. Viscidi, et al. 2007. Case-control study of human papillomavirus and oropharyngeal cancer. N. Engl. J. Med. 356: 1944-1956.
Mork, J., A.K. Lie, E. Glattre, et al. 2001. Human papillomavirus infection as a risk factor for squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 344: 1125-1131.
Smith, E.M., J.M. Ritchie, M. Pawlita, et al. 2007. Human papillomavirus seropositivity and risks of head and neck cancer. Int. J. Cancer 120: 825-832.
Achour, M., D. Zeghal, L. Kochbati, et al. 2008. Antibody response for L1, E6, E7 HPV 16, and HPV 18 antigens in Tunisian women with cervical cancer. J. Immunoassay Immunochem. 30: 82-96.
Meschede, W., K. Zumbach, J. Braspenning, et al. 1998. Antibodies against early proteins of human papillomaviruses as diagnostic markers for invasive cervical cancer. J. Clin. Microbiol. 36: 475-480.
Reuschenbach, M., T. Waterboer, K.-L. Wallin, et al. 2008. Characterization of humoral immune responses against p16, p53, HPV16 E6 and HPV16 E7 in patients with HPV-associated cancers. Int. J. Cancer 123: 2626-2631.
IARC. 2012. IARC monographs on the evaluation of carcinogenic risks to humans. International Agency for Research on Cancer. Vol. 100, pp. 1-441.
Ribeiro, K.B., J.E. Levi, M. Pawlita, et al. 2011. Low human papillomavirus prevalence in head and neck cancer: results from two large case-control studies in high-incidence regions. Int. J. Epidemiol. 40: 489-502.
Smith, E.M., L.M. Rubenstein, T.H. Haugen, et al. 2012. Complex etiology underlies risk and survival in head and neck cancer human papillomavirus, tobacco, and alcohol: a case for multifactor disease. J. Oncol. 2012. https://doi.org/10.1155/2012/571862.
Waterboer, T., P. Sehr, K.M. Michael, et al. 2005. Multiplex human papillomavirus serology based on in situ-purified glutathione s-transferase fusion proteins. Clin. Chem. 51: 1845-1853.
Sitas, F., S. Egger, M.I. Urban, et al. 2012. InterSCOPE study: associations between esophageal squamous cell carcinoma and human papillomavirus serological markers. J. Natl. Cancer Inst. 104: 147-158.
Clifford, G.M., H.R. Shin, J.K. Oh, et al. 2007. Serologic response to oncogenic human papillomavirus types in male and female university students in Busan, South Korea. Cancer Epidemiol. Biomarkers Prev. 16: 1874-1879.
Kreimer, A.R., M. Johansson, T. Waterboer, et al. 2013. Evaluation of human papillomavirus antibodies and risk of subsequent head and neck cancer. J. Clin. Oncol. 31: 2708-2715.
Kreimer, A.R., M. Johansson, E.L. Yanik, et al. 2017. Kinetics of the human papillomavirus type 16 E6 antibody response prior to oropharyngeal cancer. J. Natl. Cancer Inst. 109. https://doi.org/10.1093/jnci/djx005.
Antonsson, A., A.C. Green, K.A. Mallitt, et al. 2010. Prevalence and stability of antibodies to 37 human papillomavirus types-a population-based longitudinal study. Virology 407: 26-32.
Lehtinen, M., M. Pawlita, K. Zumbach, et al. 2003. Evaluation of antibody response to human papillomavirus early proteins in women in whom cervical cancer developed 1 to 20 years later. Am. J. Obstet. Gynecol. 188: 49-55.
Zumbach, K., F. Kisseljov, O. Sacharova, et al. 2000. Antibodies against oncoproteins E6 and E7 of human papillomavirus types 16 and 18 in cervical-carcinoma patients from Russia. Int. J. Cancer 85: 313-318.
Anantharaman, D., T. Gheit, T. Waterboer, et al. 2013. Human papillomavirus infections and upper aero-digestive tract cancers: the ARCAGE study. J. Natl. Cancer Inst. 105: 536-545.
Heideman, D.A., T. Waterboer, M. Pawlita, et al. 2007. Human papillomavirus-16 is the predominant type etiologically involved in penile squamous cell carcinoma. J. Clin. Oncol. 25: 4550-4556.
Frazer, I.H. 2009. Interaction of human papillomaviruses with the host immune system: a well evolved relationship. Virology 384: 410-414.
Wang, S.S., M. Schiffman, R. Herrero, et al. 2004. Determinants of human papillomavirus 16 serological conversion and persistence in a population-based cohort of 10 000 women in Costa Rica. Br. J. Cancer 91: 1269-1274.
Combes, J.D., M. Pawlita, T. Waterboer, et al. 2014. Antibodies against high-risk human papillomavirus proteins as markers for invasive cervical cancer. Int. J. Cancer 135: 2453-2461.
Silins, I., E. Avall-Lundqvist, A. Tadesse, et al. 2002. Evaluation of antibodies to human papillomavirus as prognostic markers in cervical cancer patients. Gynecol. Oncol. 85: 333-338.
Castellsague, X., M. Pawlita, E. Roura, et al. 2014. Prospective seroepidemiologic study on the role of human papillomavirus and other infections in cervical carcinogenesis: evidence from the EPIC cohort. Int. J. Cancer 135: 440-452.
Halec, G., M. Schmitt, S. Egger, et al. 2016. Mucosal alpha-papillomaviruses are not associated with esophageal squamous cell carcinomas: lack of mechanistic evidence from South Africa, China and Iran and from a world-wide meta-analysis. Int. J. Cancer 139: 85-98.
Lagergren, J., Z. Wang, R. Bergstrom, et al. 1999. Human papillomavirus infection and esophageal cancer: a nationwide seroepidemiologic case-control study in Sweden. J. Natl. Cancer Inst. 91: 156-162.
Han, C., G. Qiao, N.L. Hubbert, et al. 1996. Serologic association between human papillomavirus type 16 infection and esophageal cancer in Shaanxi Province, China. J. Natl. Cancer Inst. 88: 1467-1471.
Dillner, J., P. Knekt, J.T. Schiller, et al. 1995. Prospective seroepidemiological evidence that human papillomavirus type 16 infection is a risk factor for oesophageal squamous cell carcinoma. BMJ 311: 1346.
Bjorge, T., T. Hakulinen, A. Engeland, et al. 1997. A prospective, seroepidemiological study of the role of human papillomavirus in esophageal cancer in Norway. Cancer Res. 57: 3989-3992.
Holzinger, D., G. Wichmann & L. Baboci. 2017. Sensitivity and specificity of antibodies against HPV E6 and other early proteins for the detection of HPV16-driven oropharyngeal squamous cell carcinoma. Int. J. Cancer 140: 2748-2757.
Carter, J.J., L.A. Koutsky, G.C. Wipf, et al. 1996. The natural history of human papillomavirus type 16 capsid antibodies among a cohort of university women. J. Infect. Dis. 174: 927-936.
Wong, M.Y.W., B. Wang, A. Yang, et al. 2018. Human papillomavirus exposure and sexual behavior are significant risk factors for Barrett's dysplasia/esophageal adenocarcinoma. Dis. Esophagus 31. https://doi.org/10.1093/dote/doy051.
Rajendra, S. & I.K. Robertson. 2010. Similar immunogenetics of Barrett's oesophagus and cervical neoplasia: is HPV the common denominator? J. Clin. Pathol. 63: 1-3.